South Africa Rolls Out New Preventive HIV Shot in 'Major Turning Point' • FRANCE 24 English
Why It Matters
The injection’s near‑perfect efficacy and biannual dosing could dramatically lower HIV transmission rates, easing the financial and logistical strain of daily prophylaxis and accelerating the continent’s goal to end AIDS.
Key Takeaways
- •South Africa launches generic lenacapavir injection for HIV prevention.
- •Two-yearly shots offer 99.9% protection, replacing daily pills.
- •Initial batch: ~38,000 doses for high‑risk groups in six provinces.
- •Government targets 3 million users in three years, allocating $72 M.
- •International funders back affordable generic production for 120‑country rollout.
Summary
South Africa has begun distributing a generic version of lenacapavir, an injectable long‑acting HIV‑prevention drug, marking a shift from daily oral pills to twice‑yearly shots.
The first shipment contains just under 38,000 doses, earmarked for high‑risk populations—adolescent girls, young women, pregnant and breastfeeding mothers—across six provinces. The government plans to reach three million people within three years, allocating roughly $72 million, supplemented by international donors.
According to FR24 correspondent Eunice Mason, lenacapavir delivers about 99.9 % efficacy and differs from the earlier cabotegravir regimen, which required two‑month protection and was deemed too costly. Six manufacturers have been licensed to produce generic supplies for roughly 120 countries, and South Africa hopes to secure local production by next year.
If the rollout succeeds, the reduced dosing burden and lower price could dramatically curb new HIV infections, supporting South Africa’s ambition to eliminate AIDS as a public health threat by 2030 and setting a model for other high‑prevalence nations.
Comments
Want to join the conversation?
Loading comments...